The server is under maintenance between 08:00 to 12:00 (GMT+08:00), and please visit later.
We apologize for any inconvenience caused
Login  | Sign Up  |  Oriprobe Inc. Feed
China/Asia On Demand
Journal Articles
Laws/Policies/Regulations
Companies/Products
Bookmark and Share
Study of antiangiogenesis agent bevacizumab in colorectal cancer
Author(s): 
Pages: 525-528
Year: Issue:  7
Journal: JOURNAL OF INTERNATIONAL ONCOLOGY

Keyword:  结肠直肠肿瘤抗体单克隆生物疗法血管内皮生长因子类;
Abstract: 抗血管生成剂bevacizumab能靶向结合血管内皮生长因子,从而抑制肿瘤血管新生;各期临床试验结果均显示可使结直肠癌患者获益.目前认为5 mg/kg,每2周1次静脉注射的给药方式安全有效.bevacizumab的不良反应主要有高血压、蛋白尿、创伤愈合延迟、出血、胃肠穿孔和动静脉血栓事件.
Related Articles
No related articles found